Difference between revisions of "Ibrutinib (Imbruvica)"
m |
|||
Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
+ | |||
+ | ==Diseases for which it is used== | ||
+ | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
+ | *[[Mantle cell lymphoma]] | ||
+ | *[[Waldenström macroglobulinemia]] | ||
==Patient drug information== | ==Patient drug information== | ||
Line 24: | Line 29: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
+ | [[Category:Oral Chemotherapy]] | ||
+ | |||
+ | [[Category:Kinase inhibitors]] | ||
[[Category:BTK inhibitors]] | [[Category:BTK inhibitors]] | ||
+ | |||
[[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
[[Category:Mantle cell lymphoma medications]] | [[Category:Mantle cell lymphoma medications]] | ||
+ | [[Category:Waldenström macroglobulinemia medications]] | ||
+ | |||
[[Category:Drugs FDA approved in 2013]] | [[Category:Drugs FDA approved in 2013]] |
Revision as of 00:02, 13 November 2014
General information
Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade and cytokine receptor pathways. BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies. Inhibition of BTK interferes with the processes above, as well as B-cell chemotaxis and trafficking.[1][2][3]
[4]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Mantle cell lymphoma
- Waldenström macroglobulinemia
Patient drug information
- Ibrutinib (Imbruvica) package insert[1]
- Ibrutinib (Imbruvica) patient drug information (Chemocare)[5]
- Ibrutinib (Imbruvica) patient drug information (UpToDate)[6]
History of changes in FDA indication
- 11/13/2013: FDA granted accelerated approval "for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy."
- 2/12/2014: FDA granted accelerated approval "for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy."
- 7/28/2014: Approval expanded to include patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion).
Also known as
PCI-32765
References
- ↑ 1.0 1.1 1.2 Ibrutinib (Imbruvica) package insert
- ↑ Ibrutinib (Imbruvica) package insert (locally hosted backup)
- ↑ Imbruvica manufacturer's website
- ↑ Pharmacyclics BTK inhibitor website
- ↑ Ibrutinib (Imbruvica) patient drug information (Chemocare)
- ↑ Ibrutinib (Imbruvica) patient drug information (UpToDate)